Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Adma Biologics (ADMA) EBT Margin: 2011-2025

Historic EBT Margin for Adma Biologics (ADMA) over the last 11 years, with Sep 2025 value amounting to 35.40%.

  • Adma Biologics' EBT Margin rose 473.00% to 35.40% in Q3 2025 from the same period last year, while for Sep 2025 it was 31.88%, marking a year-over-year increase of 1272.00%. This contributed to the annual value of 29.48% for FY2024, which is 4042.00% up from last year.
  • Adma Biologics' EBT Margin amounted to 35.40% in Q3 2025, which was up 7.69% from 32.87% recorded in Q2 2025.
  • In the past 5 years, Adma Biologics' EBT Margin ranged from a high of 35.40% in Q3 2025 and a low of -114.26% during Q1 2021.
  • In the last 3 years, Adma Biologics' EBT Margin had a median value of 29.14% in 2025 and averaged 15.41%.
  • As far as peak fluctuations go, Adma Biologics' EBT Margin spiked by 15,346bps in 2021, and later slumped by 58bps in 2025.
  • Quarterly analysis of 5 years shows Adma Biologics' EBT Margin stood at -30.01% in 2021, then surged by 641bps to -23.59% in 2022, then decreased by 28bps to -23.88% in 2023, then spiked by 5,341bps to 29.53% in 2024, then skyrocketed by 473bps to 35.40% in 2025.
  • Its EBT Margin stands at 35.40% for Q3 2025, versus 32.87% for Q2 2025 and 29.14% for Q1 2025.